Beacon Therapeutics may have found a guiding light in a disease area where other companies have stumbled with its laruparetigene zovaparvovec (laru-zova), a gene therapy that proved early improvements ...
A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...
Genetics aren't necessarily destiny for those with mutations thought to always cause inherited blindness, a new study says. Fewer than 30% of people with these genetic variants wind up blind, even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results